Fresenius Kabi Malaysia SDN BHD Pharmaceutical Import Profile — Malaysia (DGFT 2022–2026)

Name: Fresenius Kabi Malaysia SDN BHD Pharmaceutical Import Records from India — 8 Products, $3.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Malaysia SDN BHD — Pharmaceutical Importer Profile (2026) | 8 Products, $3.5M Trade | TransData Nexus

Fresenius Kabi Malaysia SDN BHD

Pharmaceutical Importer · Malaysia · Oncology Focus · $3.5M Total Trade · DGFT Verified

Fresenius Kabi Malaysia SDN BHD is a pharmaceutical importer based in Malaysia with a total trade value of $3.5M across 8 products in 2 therapeutic categories. Based on 122 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fresenius Kabi Malaysia SDN BHD sources from 2 verified Indian suppliers, with Fresenius Kabi Oncology Limited accounting for 98.0% of imports.

Fresenius Kabi Malaysia SDN BHD — Import Portfolio & Supplier Network

Fresenius Kabi Malaysia SDN BHD import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Malaysia SDN BHD?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fresenius Kabi Oncology Limited	$4.4M	228	98.0%
Gland Pharma Limited	$88.7K	4	2.0%

Fresenius Kabi Malaysia SDN BHD sources from 2 verified Indian suppliers across .

What Formulations Does Fresenius Kabi Malaysia SDN BHD Import?

Formulation	Value	Ships
Anthracin (epirubicin) hcl injection	$166.9K	4
Kemocarb (carboplatin) BP INJ.	$158.8K	4
Oxitan oxaliplatin INJ. 50MG/10ML vialb/n: 87230416ab 87230416ac md:09/23	$150.0K	3
Anthracin (epirubicin) injection	$114.1K	3
Fytosid (etoposide) INJ. 100MG/5ML	$110.2K	4
Daxotel (docetaxel) INJ. 80MG/4ML	$100.0K	2
Gemita ( gemcitabine ) INJ. 1GM/26.3ML	$88.5K	2
Kemocarb carboplatin BP INJ.	$82.3K	2
Cytarine (cytarabine) INJ. 1GM/10ML	$68.8K	2
Dexmedetomidine hydrochloride injection200mcg/2ML,(100mcg/ML) 2ML fill in2ml vial Each	$61.9K	3
Intaxel(paclitaxel)INJ.USP 300MG/50ML	$50.0K	1
Cytarine cytarabine INJ. 1GM/10ML	$50.0K	1
Cytarine cytarabine INJ. 1GM/10ML vial, batch no. 87230369aa & 87230368aa, manufacturing . dt. 08/2023, exp. dt.	$50.0K	1
Oxitanoxaliplatininj.100MG/20ML vialb no-87230396ba manufacturing .dt. 08/2023 exp.dt.	$50.0K	1
Anthracin epirubicin hcl INJ. 50MG/25ML vial batch no. 87230424bc manufacturing . dt. 09/2023 exp. dt.	$50.0K	1

Fresenius Kabi Malaysia SDN BHD imports 195 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Carboplatin	Oncology	$730.1K	22	1.0%	14
2	Oxaliplatin	Advanced Oncology	$696.5K	19	1.5%	11
3	Docetaxel	Oncology	$524.4K	18	1.3%	15
4	Epirubicin	Advanced Oncology	$517.6K	13	8.1%	2
5	Gemcitabine	Oncology	$482.4K	27	1.0%	18
6	Cytarabine	Advanced Oncology	$276.4K	8	2.6%	8
7	Etoposide	Oncology	$180.4K	9	1.7%	11
8	Vinorelbine	Advanced Oncology	$70.8K	6	2.1%	13

Fresenius Kabi Malaysia SDN BHD imports 8 pharmaceutical products across 2 categories into Malaysia totaling $3.5M.

Fresenius Kabi Malaysia SDN BHD — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi Malaysia Sdn. Bhd., established on December 21, 2000, is a subsidiary of the global healthcare company Fresenius Kabi. The company specializes in the manufacturing, marketing, and distribution of injectable drugs, intravenous solutions, clinical nutrition products, and medical devices. These offerings support hospitals, healthcare providers, and medical institutions across Malaysia. Operating within a global healthcare network, Fresenius Kabi Malaysia emphasizes product safety, regulatory compliance, and reliable supply for clinical care.

Headquartered at 3-1 & 3-2, Axis Technology Centre, Lot 13, Jalan 51A/225, Petaling Jaya, Selangor, Malaysia, the company plays a pivotal role in Malaysia's pharmaceutical distribution landscape. By providing essential medicines and technologies for infusion, transfusion, and clinical nutrition, Fresenius Kabi Malaysia contributes significantly to the healthcare sector, ensuring that critical care solutions are accessible and reliable for patients in need.

2Distribution Network

Fresenius Kabi Malaysia Sdn. Bhd. operates from its headquarters in Petaling Jaya, Selangor, Malaysia. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Selangor suggests a well-established distribution network. This central location likely facilitates efficient logistics and geographic coverage across Malaysia, ensuring timely delivery of pharmaceutical products to healthcare providers nationwide. The company's affiliation with the global Fresenius Kabi network further enhances its distribution capabilities, potentially extending its reach beyond Malaysia to other regions in the Asia Pacific.

3Industry Role

Fresenius Kabi Malaysia Sdn. Bhd. serves as a key player in Malaysia's pharmaceutical supply chain, primarily functioning as a wholesaler and distributor. By importing and distributing a range of pharmaceutical products, including injectable drugs and medical devices, the company ensures that hospitals, healthcare providers, and medical institutions have access to essential medicines and technologies. This role is crucial in maintaining the supply of critical care solutions, thereby supporting the overall healthcare infrastructure in Malaysia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Malaysia SDN BHD

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi Malaysia Sdn. Bhd. demonstrates a high degree of supplier concentration in its sourcing strategy. The company imports finished pharmaceutical formulations from two primary suppliers: Fresenius Kabi Oncology Limited and Gland Pharma Limited. Fresenius Kabi Oncology Limited accounts for 98% of the shipments, while Gland Pharma Limited contributes the remaining 2%. This concentration indicates a strategic choice to maintain strong, long-term relationships with these suppliers, ensuring consistent product quality and supply reliability. However, such dependency also poses risks, as any disruptions with these suppliers could significantly impact Fresenius Kabi Malaysia's operations. The shipment data suggests a stable relationship with these suppliers, as evidenced by the consistent volume of imports over the years. Nonetheless, the company may consider diversifying its supplier base to mitigate potential risks associated with over-reliance on a limited number of suppliers.

2Supply Chain Resilience

Fresenius Kabi Malaysia Sdn. Bhd.'s supply chain resilience is closely tied to its sourcing strategy. The company's reliance on two primary suppliers for finished pharmaceutical formulations indicates a streamlined supply chain but also highlights potential vulnerabilities. The absence of backup suppliers suggests limited contingency planning for supply disruptions. Additionally, the focus on a specific range of formulations may expose the company to risks if there are changes in market demand or regulatory requirements. To enhance supply chain resilience, Fresenius Kabi Malaysia could consider diversifying its supplier base and expanding its product portfolio, thereby reducing dependency on a limited number of suppliers and formulations.

Importing Pharmaceuticals into Malaysia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malaysia

1Regulatory Authority & Framework

In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA) is the primary authority responsible for regulating pharmaceutical products. The NPRA operates under the Ministry of Health Malaysia and is tasked with ensuring the safety, efficacy, and quality of pharmaceutical products available in the country. Key legislation governing pharmaceutical imports includes the Sale of Drugs Act 1952 and the Control of Drugs and Cosmetics Regulations 1984. These regulations establish the framework for the registration, importation, and distribution of pharmaceutical products, ensuring that all medicines meet the required standards before reaching the Malaysian market.

2Import Licensing & GMP

Import licensing in Malaysia is governed by the NPRA, which requires all pharmaceutical products to be registered before they can be imported and marketed. Manufacturers and suppliers must provide evidence of Good Manufacturing Practice (GMP) certification, which can be recognized from various international standards, including EU GMP, WHO GMP, and PIC/S. This certification ensures that products are manufactured in facilities adhering to stringent quality control standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products, ensuring that all parties in the supply chain comply with regulatory standards.

Fresenius Kabi Malaysia SDN BHD — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi Malaysia Sdn. Bhd. focuses on importing finished pharmaceutical formulations in the oncology therapeutic area, with a particular emphasis on advanced oncology treatments. This strategic focus aligns with the growing demand for cancer therapies in Malaysia, driven by an increasing incidence of cancer cases and a need for advanced treatment options. By concentrating on these specific therapeutic areas, the company aims to address critical healthcare needs and position itself as a key provider of essential oncology medications in the Malaysian market.

2Sourcing Profile

The company's sourcing strategy centers on importing generic drugs from India, particularly in the oncology segment. This approach leverages India's established reputation for producing high-quality, cost-effective generic pharmaceuticals. The preference for finished formulations indicates a focus on ready-to-use products that meet Malaysian regulatory standards, ensuring compliance and facilitating efficient distribution. India's role as a major supplier aligns with Fresenius Kabi Malaysia's objective to provide reliable and affordable oncology treatments to the Malaysian healthcare system.

3Market Positioning

Seller's Guide — How to Become a Supplier to Fresenius Kabi Malaysia SDN BHD

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Malaysian market and collaborate with Fresenius Kabi Malaysia Sdn. Bhd. The company's current sourcing strategy, which heavily relies on a limited number of suppliers, presents an opportunity for diversification. Indian exporters can explore this potential by offering high-quality, GMP-compliant products that meet Malaysian regulatory standards. By establishing reliable supply chains and demonstrating product efficacy, new suppliers can position themselves as valuable partners to Fresenius Kabi Malaysia, thereby expanding their market presence in Malaysia.

2Requirements & Qualifications

Indian exporters seeking to supply Fresenius Kabi Malaysia Sdn. Bhd. must ensure that their products are registered with the NPRA and comply with Malaysian GMP standards. Obtaining GMP certification from recognized bodies such as the EU, WHO, or PIC/S is essential. Additionally, products must meet labeling requirements, including information in the Malay language and adherence to serialization mandates. Ensuring these qualifications will facilitate smoother entry into the Malaysian market and align with regulatory expectations.

SECTION

Frequently Asked Questions — Fresenius Kabi Malaysia SDN BHD

What products does Fresenius Kabi Malaysia SDN BHD import from India?

Fresenius Kabi Malaysia SDN BHD imports 8 pharmaceutical products across 2 categories. Top imports: Carboplatin ($730.1K), Oxaliplatin ($696.5K), Docetaxel ($524.4K), Epirubicin ($517.6K), Gemcitabine ($482.4K).

Who supplies pharmaceuticals to Fresenius Kabi Malaysia SDN BHD from India?

Fresenius Kabi Malaysia SDN BHD sources from 2 verified Indian suppliers. The primary supplier is Fresenius Kabi Oncology Limited (98.0% of imports, $4.4M).

What is Fresenius Kabi Malaysia SDN BHD's total pharmaceutical import value?

Fresenius Kabi Malaysia SDN BHD's total pharmaceutical import value from India is $3.5M, based on 122 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Malaysia SDN BHD focus on?

Fresenius Kabi Malaysia SDN BHD imports across 2 categories. The largest: Oncology (55.1%), Advanced Oncology (44.9%).

Get Full Fresenius Kabi Malaysia SDN BHD Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.